Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
NBRV was delisted on the 31st of July, 2023.
13 hedge funds and large institutions have $182K invested in Nabriva Therapeutics plc Ordinary Shares Ireland in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 2 closing their positions.
24% more capital invested
Capital invested by funds: $147K → $182K (+$34.5K)
0% more funds holding
Funds holding: 13 → 13 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$49.2K |
| 2 |
Renaissance Technologies
New York
|
+$5.52K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.35K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$88 |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$18 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IA
IFP Advisors
Tampa,
Florida
|
-$1.48K |
| 2 |
Morgan Stanley
New York
|
-$86 |
| 3 |
VFA
Values First Advisors
Gray,
Tennessee
|
-$51 |
| 4 |
Wells Fargo
San Francisco,
California
|
-$13 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VFA
1
Values First Advisors
Gray,
Tennessee
| $48.9K | -$51 | -23 | -0.1% |
|
|
2
Renaissance Technologies
New York
| $44K | +$5.52K | +2,500 | +12% |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $41K | +$49.2K | +22,294 | New |
|
|
FLSM
4
Frazier Life Sciences Management
Palo Alto,
California
| $32.2K | – | – | – |
|
|
5
Morgan Stanley
New York
| $8.39K | -$86 | -39 | -0.9% |
|
|
6
Osaic Holdings
Scottsdale,
Arizona
| $4K | +$18 | +8 | +0.4% |
|
|
7
UBS Group
Zurich,
Switzerland
| $1.88K | +$1.35K | +611 | +160% |
|
|
IA
8
IFP Advisors
Tampa,
Florida
| $1K | -$1.48K | -672 | -96% |
|
|
9
Bank of America
Charlotte,
North Carolina
| $174 | +$88 | +40 | +77% |
|
|
AA
10
Addison Advisors
Middlebury,
Vermont
| $15 | – | – | – |
|
|
11
Wells Fargo
San Francisco,
California
| $9 | -$13 | -6 | -55% |
|
|
TRCT
12
Tower Research Capital (TRC)
New York
| – | +$18 | +8 | New |
|
NBRV Hedge Fund Activity: Q4 2022 in Review
13 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) for Q4 2022, worth a combined $182K — up 24% from $147K a quarter earlier.
Fund positioning in NBRV was balanced in Q4 2022: 2 funds opened new positions, 2 closed out, 4 added to existing stakes and 4 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $49.2K. The largest seller was IFP Advisors, cutting an estimated $1.48K.
- 13 institutional investors held Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $182K of Nabriva Therapeutics plc Ordinary Shares Ireland stock for Q4 2022, up 24% quarter-over-quarter.
- 2 funds opened new Nabriva Therapeutics plc Ordinary Shares Ireland positions in Q4 2022 and 2 closed out, a net change of 0 holders.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland buyer in Q4 2022 was Susquehanna International Group, an estimated $49.2K added.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland seller in Q4 2022 was IFP Advisors, an estimated $1.48K sold.
Based on aggregated 13F filings for Q4 2022.